MV140 mucosal bacterial vaccine improves uropathogenic E. coli clearance in an experimental model of urinary tract infection.
Marianne LigonCarmen Diez-RiveroDiego García-AyusoSoumitra MohantyLaura ConejeroAnnelie BraunerJosé SubizaIndira MysorekarPaula Saz-LealPublished in: Research square (2023)
MV140 is a mucosal vaccine of inactivated whole bacteria ( E. coli, K. pneumoniae, E. faecalis, P. vulgaris ) with clinical efficacy against recurrent urinary tract infections (UTIs). Here, MV140 was evaluated in a murine model of acute uropathogenic E. coli (UPEC)-induced UTI using the UTI89 strain. MV140 vaccination resulted in UPEC clearance, concomitant with increased influx of myeloid cells in urine, CD4+ T cells in the bladder, and a systemic adaptive immune response to both MV140-containing E. coli and UTI89.
Keyphrases
- urinary tract infection
- escherichia coli
- drug induced
- induced apoptosis
- biofilm formation
- bone marrow
- spinal cord injury
- liver failure
- respiratory failure
- dendritic cells
- diabetic rats
- cell cycle arrest
- high glucose
- ulcerative colitis
- cystic fibrosis
- staphylococcus aureus
- acute respiratory distress syndrome
- intensive care unit
- stress induced
- urinary tract